Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings for Novavax, Inc. (NVAX)
Earnings in 2023 (TTM): $-543,031,000
According to Novavax, Inc.'s latest financial reports the company's current earnings (TTM) are $-543,031,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Novavax, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-543,031,000 | $-545,062,000 |
| 2022 | $-653,647,000 | $-657,939,000 |
| 2021 | $-1,714,536,000 | $-1,743,751,000 |
| 2020 | $-418,259,000 | $-427,505,000 |
| 2019 | $-132,694,000 | $-130,102,000 |
| 2018 | $-184,748,000 | $-184,748,000 |
| 2017 | $-183,769,000 | $-183,769,000 |
| 2016 | $-279,966,000 | $-279,966,000 |
| 2015 | $-156,937,000 | $-156,937,000 |
| 2014 | $-82,947,000 | $-82,947,000 |
| 2013 | $-51,958,000 | $-51,983,000 |
| 2012 | $-28,507,000 | $-28,507,000 |
| 2011 | $-18,952,000 | $-19,364,000 |
| 2010 | $-36,158,000 | $-35,708,000 |
| 2009 | $-38,374,000 | $-38,374,000 |
| 2008 | $-36,049,000 | $-36,049,000 |
| 2007 | $-34,765,000 | $-34,765,000 |
| 2006 | $-23,068,000 | $-23,068,000 |
| 2005 | $-11,174,000 | $-11,174,000 |
| 2004 | $-25,920,000 | $-25,920,000 |
| 2003 | $-17,273,000 | $-17,273,000 |
| 2002 | $-22,697,000 | $-22,697,000 |
| 2001 | $-9,745,000 | $-9,745,000 |
| 2000 | $ | $-12,191,000 |
| 1999 | $ | $-4,500,000 |
| 1998 | $-4,900,000 | $-4,800,000 |
| 1997 | $-4,600,000 | $-4,500,000 |
| 1996 | $-5,400,000 | $-5,500,000 |